keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressant augmentation

keyword
https://www.readbyqxmd.com/read/28208711/antidepressant-effects-of-aripiprazole-augmentation-for-cilostazol-treated-mice-exposed-to-chronic-mild-stress-after-ischemic-stroke
#1
Yu Ri Kim, Ha Neui Kim, Ki Whan Hong, Hwa Kyoung Shin, Byung Tae Choi
The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS). Compared to treatment with either APZ or CLS alone, the combined treatment resulted in a greater reduction in depressive behaviors, including anhedonia, despair-like behaviors, and memory impairments. This treatment also significantly reduced atrophic changes in the striatum, cortex, and midbrain of CMS-treated ischemic mice, and inhibited neuronal cell apoptosis, particularly in the striatum and the dentate gyrus of the hippocampus...
February 8, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28204956/centrally-targeted-pharmacotherapy-for-chronic-abdominal-pain-understanding-and-management
#2
Hans Törnblom, Douglas A Drossman
Chronic abdominal pain has a widespread impact on the individual and the society. Identifying and explaining mechanisms of importance for the pain experience within a biopsychosocial context are central in order to select treatment that has a chance for symptom reduction. With current knowledge of brain-gut interactions, chronic abdominal pain, which mostly appears in functional gastrointestinal disorders, to a large extent involves pain mechanisms residing within the brain. As such, the use of centrally targeted pharmacotherapy as an effective treatment option is obvious in a selected number of patients...
February 16, 2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/28143768/long-lasting-effects-of-fluoxetine-and-or-exercise-augmentation-on-bio-behavioural-markers-of-depression-in-pre-pubertal-stress-sensitive-rats
#3
Jacobus C Schoeman, Stephanus F Steyn, Brian H Harvey, Christiaan B Brink
Juvenile depression is of great concern with only limited treatment currently approved. Delayed onset of action, low remission and high relapse rates, and potential long-lasting consequences further complicates treatment and highlights the need for new treatment options. Studies reporting on long-lasting effects of early-life treatment have reported conflicting results, with the pre-adolescent period mostly overlooked. The anti-depressive effect of exercise, as a possible treatment option or augmentation strategy, is dependent on age and exercise intensity...
January 29, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28138040/comparative-effects-of-ly3020371-a-potent-and-selective-mglu2-3-receptor-antagonist-and-ketamine-a-non-competitive-nmda-receptor-antagonist-in-rodents-evidence-supporting-use-for-the-treatment-of-depression
#4
Jeffrey M Witkin, Stephen Mitchell, Keith Wafford, Guy Carter, Gary Gilmour, Jennifer Li, Brian Eastwood, Carl Overshiner, Xia Li, Linda Rorick-Kehn, Kurt Rasmussen, Wesley Anderson, Alexander Nikolayev, Vladamir Tolstikov, Ming-Shang Kuo, John Catlow, Renhua Li, Stephen Smith, Charles Mitch, Paul Ornstein, Stephen Swanson, James Monn
The ability of the NMDA receptor antagonist ketamine to alleviate symptoms in patients suffering from treatment resistant depression (TRD) is well documented. In this report, we directly compare in vivo biological responses in rodents elicited by a recently discovered mGlu2/3 receptor antagonist (LY3020371) with those produced by ketamine. Both LY3020371 and ketamine increased the number of spontaneously active DA cells in the ventral tegmental area of anesthetized rats, increased O2 in the anterior cingulate cortex, promoted wakefulness, enhanced the efflux of biogenic amines in the prefrontal cortex, and produced antidepressant-related behavioral effects in SSRI-sensitive and -insensitive rodent models...
January 30, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28125813/signal-transduction-underlying-the-inhibitory-mechanism-of-fluoxetine-on-electrical-field-stimulation-response-in-rat-ileal-smooth-muscle
#5
Phyu Phyu Khin, Tin Sandar Zaw, Uy Dong Sohn
Fluoxetine (FLX), a well-known antidepressant drug under the class of selective serotonin reuptake inhibitor, exerts its action by inhibiting the reuptake of serotonin selectively. In some studies, it has been demonstrated that FLX relaxes the intestinal smooth muscle. In this study, we aimed at studying the signal transduction pathway underlying the muscle relaxation effect of FLX on electrically stimulated rat ileal muscle contraction. To investigate the possible mechanism involved, various antagonists were used...
January 27, 2017: Pharmacology
https://www.readbyqxmd.com/read/28122091/d-cycloserine-augmentation-of-exposure-based-cognitive-behavior-therapy-for-anxiety-obsessive-compulsive-and-posttraumatic-stress-disorders-a-systematic-review-and-meta-analysis
#6
David Mataix-Cols, Lorena Fernández de la Cruz, Benedetta Monzani, David Rosenfield, Erik Andersson, Ana Pérez-Vigil, Paolo Frumento, Rianne A de Kleine, JoAnn Difede, Boadie W Dunlop, Lara J Farrell, Daniel Geller, Maryrose Gerardi, Adam J Guastella, Stefan G Hofmann, Gert-Jan Hendriks, Matt G Kushner, Francis S Lee, Eric J Lenze, Cheri A Levinson, Harry McConnell, Michael W Otto, Jens Plag, Mark H Pollack, Kerry J Ressler, Thomas L Rodebaugh, Barbara O Rothbaum, Michael S Scheeringa, Anja Siewert-Siegmund, Jasper A J Smits, Eric A Storch, Andreas Ströhle, Candyce D Tart, David F Tolin, Agnes van Minnen, Allison M Waters, Carl F Weems, Sabine Wilhelm, Katarzyna Wyka, Michael Davis, Christian Rück
Importance: Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear. Objective: To clarify whether DCS is superior to placebo in augmenting the effects of cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether antidepressants interact with DCS and the effect of potential moderating variables...
January 25, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28097008/preclinical-findings-predicting-efficacy-and-side-effect-profile-of-ly2940094-an-antagonist-of-nociceptin-receptors
#7
Jeffrey M Witkin, Linda M Rorick-Kehn, Mark J Benvenga, Benjamin L Adams, Scott D Gleason, Karen M Knitowski, Xia Li, Steven Chaney, Julie F Falcone, Janice W Smith, Julie Foss, Kirsti Lloyd, John T Catlow, David L McKinzie, Kjell A Svensson, Vanessa N Barth, Miguel A Toledo, Nuria Diaz, Celia Lafuente, Alma Jiménez, Alfonso Benito, Conception Pedregal, Maria A Martínez-Grau, Anke Post, Michael A Ansonoff, John E Pintar, Michael A Statnick
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide whose receptor is designated ORL1 or nociceptin receptor (NOP). We utilized a potent, selective, and orally bioavailable antagonist with documented engagement with NOP receptors in vivo to assess antidepressant- and anxiolytic-related pharmacological effects of NOP receptor blockade along with measures of cognitive and motor impingement. LY2940094 ([2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol) displayed antidepressant-like behavioral effects in the forced-swim test in mice, an effect absent in NOP (-/-) mice...
December 2016: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28096676/aripiprazole-augmentation-in-managing-comorbid-obsessive-compulsive-disorder-and-bipolar-disorder-a-case-with-suicidal-attempts
#8
Jianbo Lai, Qiaoqiao Lu, Peng Zhang, Tingting Xu, Yi Xu, Shaohua Hu
Comorbid obsessive-compulsive disorder (OCD) and bipolar disorder (BD) have long been an intractable problem in clinical practice. The increased risk of manic/hypomanic switch hinders the use of antidepressants for managing coexisting OCD symptoms in BD patients. We herein present a case of a patient with BD-OCD comorbidity, who was successfully treated with mood stabilizers and aripiprazole augmentation. The young female patient reported recurrent depressive episodes and aggravating compulsive behaviors before hospitalization...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28004621/augmentation-of-phenelzine-with-aripiprazole-and-quetiapine-in-a-treatment-resistant-patient-with-psychotic-unipolar-depression-case-report-and-literature-review
#9
Jonathan M Meyer, Michael A Cummings, George Proctor
Irreversible monoamine oxidase inhibitor (MAOI) antidepressants have significant efficacy in treatment-resistant unipolar depression, but in some instances patients may not achieve remission. Among the adjunctive and augmentation strategies, certain second-generation antipsychotics (SGAs) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. Clinicians may eschew SGA options in part due to the limited literature on SGA-MAOI combinations, with only one published case involving aripiprazole, and none for olanzapine, lurasidone, or brexpiprazole...
December 22, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27908707/the-role-of-nmda-receptor-and-nitric-oxide-cyclic-guanosine-monophosphate-pathway-in-the-antidepressant-like-effect-of-dextromethorphan-in-mice-forced-swimming-test-and-tail-suspension-test
#10
Ehsan Sakhaee, Sattar Ostadhadi, Muhammad Imran Khan, Farbod Yousefi, Abbas Norouzi-Javidan, Reyhaneh Akbarian, Mohsen Chamanara, Samira Zolfaghari, Ahmad-Reza Dehpour
Depression is a devastating disorder which has a high impact on the wellbeing of overall society. As such, need for innovative therapeutic agents are always there. Most of the researchers focused on N-methyl-d-aspartate receptor to explore the antidepressant like activity of new therapeutic agents. Dextromethorphan is a cough suppressant agent with potential antidepressant activity reported in mouse force swimming test. Considering N-methyl-d-aspartate as a forefront in exploring antidepressant agents, here we focused to unpin the antidepressant mechanism of dextromethorphan targeting N-methyl-d-aspartate receptor induced nitric oxide-cyclic guanosine monophosphate signaling...
January 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27906972/selective-serotonin-reuptake-inhibitor-ssri-antidepressants-in-pregnancy-and-congenital-anomalies-analysis-of-linked-databases-in-wales-norway-and-funen-denmark
#11
Sue Jordan, Joan K Morris, Gareth I Davies, David Tucker, Daniel S Thayer, Johannes M Luteijn, Margery Morgan, Ester Garne, Anne V Hansen, Kari Klungsøyr, Anders Engeland, Breidge Boyle, Helen Dolk
BACKGROUND: Hypothesised associations between in utero exposure to selective serotonin reuptake inhibitors (SSRIs) and congenital anomalies, particularly congenital heart defects (CHD), remain controversial. We investigated the putative teratogenicity of SSRI prescription in the 91 days either side of first day of last menstrual period (LMP). METHODS AND FINDINGS: Three population-based EUROCAT congenital anomaly registries- Norway (2004-2010), Wales (2000-2010) and Funen, Denmark (2000-2010)-were linked to the electronic healthcare databases holding prospectively collected prescription information for all pregnancies in the timeframes available...
2016: PloS One
https://www.readbyqxmd.com/read/27865100/walking-away-from-depression-motor-activity-increases-ratings-of-mood-and-incentive-drive-in-patients-with-major-depression
#12
Bettina Heike Bewernick, Anne Sarah Urbach, Arndt Bröder, Sarah Kayser, Thomas Eduard Schlaepfer
Reduced motor activity is associated with depression. Lewinsohn's cognitive behavioural model of depression assumes a lack of positive experience due to a reduced level of activity as a key aspect of depression. The acute relationship between motor activity and mood as well as between motor activity and incentive drive (the motivation to engage in activities) is unknown. An augmentation of mood and incentive drive could precede or follow motor activity. We examined (1) whether motor activity would be correlated with the course of depression and (2) the temporal relationship between motor activity and acute changes in mood and incentive drive...
January 2017: Psychiatry Research
https://www.readbyqxmd.com/read/27852967/-results-of-investigations-on-the-association-between-lithium-levels-in-drinking-water-and-suicidal-behaviour-in-the-population-a-narrative-review
#13
Anna Hidvégi, Zoltán Rihmer, Péter Döme
INTRODUCTION: The risk of suicide is determined by the interplay of several interrelated factors from which psychiatric (especially affective) disorders are the most powerful predictors. Lithium, a mood stabilizer (which is also used to augment the efficacy of antidepressant therapy) has a well-established antisuicidal effect. In the last decades several studies investigated whether there is an association between the amount of lithium in tap water and suicide risk in the population. METHODS: A PubMed search was conducted to identify papers investigated the association between lithium levels in drinking water and suicide risk of the population...
2016: Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata
https://www.readbyqxmd.com/read/27848269/evidence-based-pharmacotherapy-of-treatment-resistant-unipolar-depression
#14
Markus Dold, Siegfried Kasper
Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities...
November 16, 2016: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/27844095/antidepressant-effects-of-combination-of-brexpiprazole-and-fluoxetine-on-depression-like-behavior-and-dendritic-changes-in-mice-after-inflammation
#15
Min Ma, Qian Ren, Chun Yang, Ji-Chun Zhang, Wei Yao, Chao Dong, Yuta Ohgi, Takashi Futamura, Kenji Hashimoto
RATIONALE: Addition of low doses of atypical antipsychotic drugs with selective serotonin reuptake inhibitors (SSRIs) could promote a rapid antidepressant effect in treatment-resistant patients with major depression. Brexpiprazole, a new atypical antipsychotic drug, has been used as adjunctive therapy for the treatment of major depression. OBJECTIVES: The present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression...
February 2017: Psychopharmacology
https://www.readbyqxmd.com/read/27835725/bright-light-therapy-as-augmentation-of-pharmacotherapy-for-treatment-of-depression-a-systematic-review-and-meta-analysis
#16
Thomas M Penders, Cornel N Stanciu, Alexander M Schoemann, Philip T Ninan, Richard Bloch, Sy A Saeed
Background: Bright light therapy has demonstrated efficacy and is an accepted treatment for seasonal depression. It has been suggested that bright light therapy may have efficacy in nonseasonal depressions. Also, there is evidence that bright light therapy may improve responsiveness to antidepressant pharmacotherapy. Data Sources: We searched PubMed/MEDLINE, PsycINFO, PsycARTICLES, CINAHL, EMBASE, Scopus, and Academic OneFile for English-language literature published between January 1998 and April 2016, using the keywords bright light therapy AND major depression, bright light therapy AND depress*, bright light therapy AND bipolar depression, bright light therapy AND affective disorders, circadian rhythm AND major depression, circadian rhythm AND depress*, and circadian rhythm AND affective disorder...
October 20, 2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27788337/adjunctive-brexpiprazole-for-the-treatment-of-major-depressive-disorder
#17
John L Beyer, Richard H Weisler
The lifetime prevalence of major depressive episodes in the United States is nearly 17%. Clinical trials and clinical effectiveness studies have demonstrated that many patients will fail to achieve remission using traditional monotherapy, contributing to significant morbidity and suffering. Because of this, augmentation strategies have been proposed to improve both treatment response and remission. Areas covered: Brexpiprazole is a second generation antipsychotic (SGA) approved by the US FDA in 2015 as an add-on treatment to an antidepressant medication for the treatment of adults with MDD, based on the results of two large-scale, randomized, placebo-controlled trials...
December 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27771379/novel-highly-potent-and-in%C3%A2-vivo-active-inhibitor-of-gaba-transporter-subtype-1-with-anticonvulsant-anxiolytic-antidepressant-and-antinociceptive-properties
#18
Kinga Sałat, Adrian Podkowa, Natalia Malikowska, Felix Kern, Jörg Pabel, Ewelina Wojcieszak, Katarzyna Kulig, Klaus T Wanner, Beata Strach, Elżbieta Wyska
BACKGROUND AND PURPOSE: Since GABAergic dysfunction underlies a variety of neurological and psychiatric disorders, numerous strategies leading to the augmentation of GABAergic neurotransmission have been introduced. One of them is the inhibition of GABA reuptake from the synaptic cleft mediated by four plasma membrane GABA transporters (GAT1-4). GAT1 which is exclusively expressed in the brain is an interesting target for centrally acting drugs. In this research, pharmacological properties of a novel, highly potent and selective inhibitor of GAT1, the guvacine derivative named DDPM-2571, were assessed in vivo...
February 2017: Neuropharmacology
https://www.readbyqxmd.com/read/27769701/pain-depression-dyad-induced-by-reserpine-is-relieved-by-p-p-methoxyl-diphenyl-diselenide-in-rats
#19
Carla Elena Sartori Oliveira, Marcel Henrique Marcondes Marcondes Sari, Vanessa A Zborowski, Vinicius Costa Prado, Cristina Wayne Nogueira, Gilson Zeni
Depression and pain comorbidity represent a neuropsychiatric condition with substantial socioeconomic impact to society. The commonly used antidepressants and analgesics to treat this comorbidity have shown restricted clinical efficacy. In this way, the aim of this study was to investigate the behavioral, biochemical and neurochemical effects of a p,p'-methoxyl-diphenyl diselenide (OMePhSe)2 supplemented diet on pain-depression dyad induced by reserpine in rats. Adult Wistar rats were fed with 10mg (MeOPhSe)2 per kg of rat chow supplemented diet for 30 days...
November 15, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27766299/role-of-omega-3-fatty-acids-in-the-etiology-treatment-and-prevention-of-depression-current-status-and-future-directions
#20
Robert K McNamara
Over the past three decades a body of translational evidence has implicated dietary deficiency in long-chain omega-3 (LCn-3) fatty acids, including eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the pathophysiology and etiology of major depressive disorder (MDD). Cross-national and cross-sectional data suggest that greater habitual intake of preformed EPA+DHA is associated with reduced risk for developing depressive symptoms and syndromal MDD. Erythrocyte EPA and DHA composition is highly correlated with habitual fish or fish oil intake, and case-control studies have consistently observed lower erythrocyte EPA and/or DHA levels in patients with MDD...
September 2016: Journal of Nutrition & Intermediary Metabolism
keyword
keyword
86292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"